{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:35:00Z","timestamp":1791848100272,"version":"4.3.4"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The breast cancer (BC) susceptibility genes 1 (\n                      <jats:italic>BRCA1<\/jats:italic>\n                      ) and BC susceptibility genes 2 (\n                      <jats:italic>BRCA2<\/jats:italic>\n                      ) are critical genes associated with hereditary breast cancer, and their mutation prevalence might greatly vary across different ethnic populations. This systematic review and meta-analysis evaluated global ethnic variation in\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation prevalence among breast cancer (BC) patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We searched five databases for studies published between 2015 and 2025 that reported\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations in BC patients across various ethnic groups. 45 studies met the inclusion criteria, comprising about 44,000 BC patients. Data were stratified into two categories: (1) the frequency of all reported variants (including high-frequency polymorphisms) to assess global reporting patterns, and (2) the estimated clinical prevalence of confirmed Pathogenic and Likely Pathogenic (PLP) variants (excluding benign polymorphisms) for cancer risk assessment in broad ethnic categories (Asian, Chinese, Black\/African descent, Hispanic\/Latino, Middle Eastern\/North African, European, Ashkenazi Jewish, and others).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The prevalence of\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutations in BC patients displayed substantial global variability. Heterogeneity was high (I\u00b2 &gt;95%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), reflecting diverse study populations and designs. The frequency of all reported variants varied substantially, reaching up to 17% in specific subgroups due to the inclusion of common polymorphisms. However, after strict filtering, the clinical prevalence of PLP variants ranged from &lt;\u20091% to 5% in most ethnic groups, aligning with expected population risk.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Ethnicity significantly influences\n                      <jats:italic>BRCA1\/2<\/jats:italic>\n                      mutation distribution among BC patients globally. These findings underscore the importance of population-tailored genetic testing approaches and the necessity of including underrepresented groups in genetic research to enhance risk assessment and personalized cancer care.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07997-3","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:54:42Z","timestamp":1773312882000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Global prevalence and ethnic variation of pathogenic BRCA1\/2 variants in breast cancer: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Najeeb Ullah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijun","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhen","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruijiao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xukai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana S.","family":"Alqarni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4677-0361","authenticated-orcid":false,"given":"Tianhui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"issue":"9","key":"7997_CR1","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1038\/s41416-024-02827-z","volume":"131","author":"B Arun","year":"2024","unstructured":"Arun B, Couch FJ, Abraham J, Tung N, Fasching PA. BRCA-mutated breast cancer: the unmet need, challenges and therapeutic benefits of genetic testing. Br J Cancer. 2024;131(9):1400\u201314.","journal-title":"Br J Cancer"},{"issue":"2","key":"7997_CR2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41416-018-0127-5","volume":"119","author":"NM Tung","year":"2018","unstructured":"Tung NM, Garber JE. BRCA1\/2 testing: therapeutic implications for breast cancer management. Br J Cancer. 2018;119(2):141\u201352.","journal-title":"Br J Cancer"},{"issue":"2","key":"7997_CR3","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40487-021-00162-4","volume":"9","author":"JM Collins","year":"2021","unstructured":"Collins JM, Nordstrom BL, McLaurin KK, Dalvi TB, McCutcheon SC, Bennett JC, et al. A Real-World Evidence Study of CDK4\/6 Inhibitor Treatment Patterns and Outcomes in Metastatic Breast Cancer by Germline BRCA Mutation Status. Oncol Ther. 2021;9(2):575\u201389.","journal-title":"Oncol Ther"},{"key":"7997_CR4","doi-asserted-by":"publisher","first-page":"112944","DOI":"10.1016\/j.ejca.2023.112944","volume":"190","author":"C Valenza","year":"2023","unstructured":"Valenza C, Trapani D, Gandini S, Sposetti C, Boscolo Bielo L, Marra A, et al. Platinum-based chemotherapy and PARP inhibitors for patients with a germline BRCA pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments. Eur J Cancer. 2023;190:112944.","journal-title":"Eur J Cancer"},{"key":"7997_CR5","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.ejca.2020.12.023","volume":"146","author":"P Pujol","year":"2021","unstructured":"Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, et al. Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer. 2021;146:30\u201347.","journal-title":"Eur J Cancer"},{"key":"7997_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.2147\/CLEP.S206949","volume":"11","author":"N Armstrong","year":"2019","unstructured":"Armstrong N, Ryder S, Forbes C, Ross J, Quek RG. A systematic review of the international prevalence of BRCA mutation in breast cancer. Clin Epidemiol. 2019;11:543\u201361.","journal-title":"Clin Epidemiol"},{"issue":"23","key":"7997_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","volume":"317","author":"KB Kuchenbaecker","year":"2017","unstructured":"Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402.","journal-title":"JAMA"},{"issue":"4","key":"7997_CR8","doi-asserted-by":"publisher","first-page":"357","DOI":"10.4048\/jbc.2013.16.4.357","volume":"16","author":"H Kim","year":"2013","unstructured":"Kim H, Choi DH. Distribution of BRCA1 and BRCA2 Mutations in Asian Patients with Breast Cancer. J Breast Cancer. 2013;16(4):357.","journal-title":"J Breast Cancer"},{"key":"7997_CR9","doi-asserted-by":"publisher","first-page":"834265","DOI":"10.3389\/fgene.2022.834265","volume":"13","author":"NC n Der Merwe","year":"2022","unstructured":"n Der Merwe NC, Combrink HM, Ntaita KS, Oosthuizen J. Prevalence of Clinically Relevant Germline BRCA Variants in a Large Unselected South African Breast and Ovarian Cancer Cohort: A Public Sector Experience. Front Genet. 2022;13:834265.","journal-title":"Front Genet"},{"issue":"6","key":"7997_CR10","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.31557\/APJCP.2024.25.6.1891","volume":"25","author":"P Gervas","year":"2024","unstructured":"Gervas P, Aleksey M, Nataliya B, Kollantay O, Evgeny C, Cherdyntseva N. A Systematic Review of the Prevalence of Germline BRCA mutations in North Asia Breast Cancer Patients. Asian Pac J Cancer Prev. 2024;25(6):1891\u2013902.","journal-title":"Asian Pac J Cancer Prev"},{"issue":"2","key":"7997_CR11","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/j.1399-0004.2010.01617.x","volume":"81","author":"N Van Der Merwe","year":"2012","unstructured":"Van Der Merwe N, Hamel N, Schneider S, Apffelstaedt J, Wijnen J, Foulkes W. A founder BRCA2 mutation in non-Afrikaner breast cancer patients of the Western Cape of South Africa. Clin Genet. 2012;81(2):179\u201384.","journal-title":"Clin Genet"},{"issue":"5","key":"7997_CR12","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/ijc.20186","volume":"110","author":"MD Reeves","year":"2004","unstructured":"Reeves MD, Yawitch TM, Van Der Merwe NC, Van Den Berg HJ, Dreyer G, Van Rensburg EJ. BRCA1 mutations in South African breast and\/or ovarian cancer families: Evidence of a novel founder mutation in Afrikaner families. Int J Cancer. 2004;110(5):677\u201382.","journal-title":"Int J Cancer"},{"key":"7997_CR13","doi-asserted-by":"crossref","unstructured":"Oosthuizen J, Van Der Kotze MJ, Myburgh EJ, Van Der Bester P. Globally rare BRCA2 variants with founder haplotypes in the South African population: implications for point-of-care testing based on a single-institution BRCA1\/2 next-generation sequencing study. Front Oncol [Internet]. 12 Feb 2021 [cited 15 Jul 2025];10. Available from: https:\/\/www","DOI":"10.3389\/fonc.2020.619469"},{"issue":"4","key":"7997_CR14","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/ijc.32176","volume":"145","author":"SP Bhaskaran","year":"2019","unstructured":"Bhaskaran SP, Chandratre K, Gupta H, Zhang L, Wang X, Cui J, et al. Germline variation in BRCA1\/2 is highly ethnic-specific: Evidence from over 30,000 Chinese hereditary breast and ovarian cancer patients. Int J Cancer. 2019;145(4):962\u201373.","journal-title":"Int J Cancer"},{"issue":"9","key":"7997_CR15","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.jclinepi.2011.11.014","volume":"65","author":"D Hoy","year":"2012","unstructured":"Hoy D, Brooks P, Woolf A, Blyth F, March L, Bain C, et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol. 2012;65(9):934\u20139.","journal-title":"J Clin Epidemiol"},{"key":"7997_CR16","doi-asserted-by":"crossref","unstructured":"Dodova RI, Mitkova AV, Dacheva DR, Hadjo LB, Vlahova AI, - Hadjieva MST, et al. Spectrum and frequencies of BRCA1\/2 mutations in Bulgarian high risk breast cancer patients. BMC Cancer [Internet]. 2015 Dec [cited 17 Jul 2025];15(1). Available from: https:\/\/bmccancer","DOI":"10.1186\/s12885-015-1516-2"},{"key":"7997_CR17","doi-asserted-by":"crossref","unstructured":"Francies FZ, Wainstein T, De Leeneer K, Cairns A, Murdoch M, Nietz S, et al. BRCA1, BRCA2 and PALB2 mutations and CHEK2 c.1100delC in different South African ethnic groups diagnosed with premenopausal and\/or triple negative breast cancer. BMC Cancer [Internet]. 2015 Dec [cited 17 Jul 2025];15(1). Available from: http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1913-6","DOI":"10.1186\/s12885-015-1913-6"},{"issue":"4","key":"7997_CR18","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1634\/theoncologist.2014-0364","volume":"20","author":"NS El Saghir","year":"2015","unstructured":"El Saghir NS, Zgheib NK, Assi HA, Khoury KE, Bidet Y, Jaber SM, et al. BRCA1 and BRCA2 Mutations in Ethnic Lebanese Arab Women With High Hereditary Risk Breast Cancer. Oncologist. 2015;20(4):357\u201364.","journal-title":"Oncologist"},{"issue":"2","key":"7997_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s10549-015-3312-8","volume":"150","author":"C Villarreal-Garza","year":"2015","unstructured":"Villarreal-Garza C, Weitzel JN, Llacuachaqui M, Sifuentes E, Magallanes-Hoyos MC, Gallardo L, et al. The prevalence of BRCA1 and BRCA2 mutations among young Mexican women with triple-negative breast cancer. Breast Cancer Res Treat. 2015;150(2):389\u201394.","journal-title":"Breast Cancer Res Treat"},{"issue":"23","key":"7997_CR20","doi-asserted-by":"publisher","first-page":"4173","DOI":"10.1002\/cncr.29645","volume":"121","author":"T Pal","year":"2015","unstructured":"Pal T, Bonner D, Cragun D, Monteiro ANA, Phelan C, Servais L, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. Cancer. 2015;121(23):4173\u201380.","journal-title":"Cancer"},{"key":"7997_CR21","doi-asserted-by":"crossref","unstructured":"Abdikhakimov A, Tukhtaboeva M, Adilov B, Turdikulova S. The potential contribution of BRCA mutations to early onset and familial breast cancer in Uzbekistan. Cent Asian J Glob Health [Internet]. 21 Dec 2016 [cited 17 Jul 2025];5(1). Available from: http:\/\/cajgh.pitt.edu\/ojs\/cajgh\/article\/view\/228.","DOI":"10.5195\/cajgh.2016.228"},{"issue":"5","key":"7997_CR22","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ijc.30143","volume":"139","author":"R Bu","year":"2016","unstructured":"Bu R, Siraj AK, Al-Obaisi KAS, Beg S, Al Hazmi M, Ajarim D, et al. Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer. 2016;139(5):1091\u20137.","journal-title":"Int J Cancer"},{"issue":"3","key":"7997_CR23","doi-asserted-by":"publisher","first-page":"627","DOI":"10.4143\/crt.2016.292","volume":"49","author":"KA Yoon","year":"2017","unstructured":"Yoon KA, Park B, Lee BI, Yang MJ, Kong SY, Lee ES. Clinically Significant Unclassified Variants in BRCA1 and BRCA2 Genes among Korean Breast Cancer Patients. Cancer Res Treat. 2017;49(3):627\u201334.","journal-title":"Cancer Res Treat"},{"issue":"2","key":"7997_CR24","doi-asserted-by":"publisher","first-page":"169","DOI":"10.18865\/ed.27.2.169","volume":"27","author":"L Ricks-Santi","year":"2017","unstructured":"Ricks-Santi L, McDonald JT, Gold B, Dean M, Thompson N, Abbas M, et al. Next Generation Sequencing Reveals High Prevalence of BRCA1 and BRCA2 Variants of Unknown Significance in Early-Onset Breast Cancer in African American Women. Ethn Dis. 2017;27(2):169.","journal-title":"Ethn Dis"},{"issue":"12","key":"7997_CR25","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1001\/jamaoncol.2017.1996","volume":"3","author":"T Walsh","year":"2017","unstructured":"Walsh T, Mandell JB, Norquist BM, Casadei S, Gulsuner S, Lee MK, et al. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women. JAMA Oncol. 2017;3(12):1647.","journal-title":"JAMA Oncol"},{"issue":"3","key":"7997_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s10549-017-4356-8","volume":"165","author":"XR Yang","year":"2017","unstructured":"Yang XR, Devi BCR, Sung H, Guida J, Mucaki EJ, Xiao Y, et al. Prevalence and spectrum of germline rare variants in BRCA1\/2 and PALB2 among breast cancer cases in Sarawak, Malaysia. Breast Cancer Res Treat. 2017;165(3):687\u201397.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7997_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.25100\/cm.v48i2.1867","volume":"48","author":"I Brice\u00f1o-Balc\u00e1zar","year":"2017","unstructured":"Brice\u00f1o-Balc\u00e1zar I, G\u00f3mez-Guti\u00e9rrez A, D\u00edaz-Duss\u00e1n NA, Noguera-Santamar\u00eda MC, D\u00edaz-Rinc\u00f3n D, Casas-G\u00f3mez MC. Mutational spectrum in breast cancer associated BRCA1 and BRCA2 genes in Colombia. Colomb Med Cali Colomb. 2017;48(2):58\u201363.","journal-title":"Colomb Med Cali Colomb"},{"key":"7997_CR28","doi-asserted-by":"crossref","unstructured":"Fang M, Zhu L, Li H, Li X, Wu Y, Wu K, et al. Characterization of mutations in BRCA1\/2 and the relationship with clinic\u2013pathological features of breast cancer in a hereditarily high\u2013risk sample of chinese population. Oncol Lett [Internet]. 2017 Dec 29 [cited 17 Jul 2025]; Available from: http:\/\/www.spandidos-publications.com\/10.3892\/ol.2017.7717","DOI":"10.3892\/ol.2017.7717"},{"key":"7997_CR29","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.12659\/MSM.905812","volume":"24","author":"Y Liang","year":"2018","unstructured":"Liang Y, Yang X, Li H, Zhu A, Guo Z, Li M. Prevalence and Spectrum of BRCA1\/2 Germline Mutations in Women with Breast Cancer in China Based on Next-Generation Sequencing. Med Sci Monit. 2018;24:2465\u201375.","journal-title":"Med Sci Monit"},{"key":"7997_CR30","doi-asserted-by":"crossref","unstructured":"Abdel-Razeq H, Al-Omari A, Zahran F, Arun B. Germline BRCA1\/BRCA2 mutations among high risk breast cancer patients in Jordan. BMC Cancer [Internet]. 2018 Dec [cited 17 Jul 2025];18(1). Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4079-1","DOI":"10.1186\/s12885-018-4079-1"},{"key":"7997_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2147\/TACG.S155955","volume":"11","author":"N Shah","year":"2018","unstructured":"Shah N, Shah P, Panchal Y, Katudia K, Khatri NB, Ray HS, et al. Mutation analysis of BRCA1\/2 mutations with special reference to polymorphic SNPs in Indian breast cancer patients. Appl Clin Genet. 2018;11:59\u201367.","journal-title":"Appl Clin Genet"},{"key":"7997_CR32","doi-asserted-by":"publisher","unstructured":"Abulkhair O, Al Balwi M, Makram O, Alsubaie L, Faris M, Shehata H, et al. Prevalence of BRCA1 and BRCA2 mutations among high-risk saudi patients with breast cancer. J Glob Oncol [Internet]. 2018 Dec [cited 17 Jul 2025];(4). Available from: https:\/\/doi.org\/10.1200\/JGO.18.00066.","DOI":"10.1200\/JGO.18.00066"},{"issue":"5","key":"7997_CR33","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.21037\/tcr.2019.08.32","volume":"8","author":"T Wang","year":"2019","unstructured":"Wang T, Zhang J, Xiao J, Huang M, Li N, Ling R. Mutational analysis of BRCA1 and BRCA2 in northwest Chinese breast cancer patients. Transl Cancer Res. 2019;8(5):1845\u201352.","journal-title":"Transl Cancer Res"},{"key":"7997_CR34","doi-asserted-by":"crossref","unstructured":"Al Hannan F, Keogh MB, Taha S, Al Buainain L. Characterization of BRCA1 and BRCA2 genetic variants in a cohort of Bahraini breast cancer patients using next-generation sequencing. Mol Genet Genomic Med [Internet]. 2019 Jul [cited 17 Jul 2025];7(7). Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mgg3.771","DOI":"10.1002\/mgg3.771"},{"key":"7997_CR35","first-page":"105","volume":"33","author":"G Khalili-Tanha","year":"2019","unstructured":"Khalili-Tanha G, Sebzari A, Moodi M, Hajipoor F, Naseri M. Mutations analysis of BRCA1 gene in patients with breast cancer in South Khorasan province, East Iran. Med J Islam Repub Iran. 2019;33:105.","journal-title":"Med J Islam Repub Iran"},{"issue":"2","key":"7997_CR36","doi-asserted-by":"publisher","first-page":"483","DOI":"10.21037\/tcr.2019.03.02","volume":"8","author":"M Shen","year":"2019","unstructured":"Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, et al. BRCA1\/2 mutation spectrum in Chinese early-onset breast cancer. Transl Cancer Res. 2019;8(2):483\u201390.","journal-title":"Transl Cancer Res"},{"key":"7997_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/9645147","volume":"2019","author":"C Geredeli","year":"2019","unstructured":"Geredeli C, Yasar N, Sakin A. Germline Mutations in BRCA1 and BRCA2 in Breast Cancer Patients with High Genetic Risk in Turkish Population. Int J Breast Cancer. 2019;2019:1\u20137.","journal-title":"Int J Breast Cancer"},{"key":"7997_CR38","doi-asserted-by":"crossref","unstructured":"Cort\u00e9s C, Rivera AL, Trochez D, Solarte M, G\u00f3mez D, Cifuentes L, et al. Mutational analysis of BRCA1 and BRCA2 genes in women with familial breast cancer from different regions of Colombia. Hered Cancer Clin Pract [Internet]. 2019 Dec [cited 17 Jul 2025];17(1). Available from: https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-019-0120-x","DOI":"10.1186\/s13053-019-0120-x"},{"key":"7997_CR39","doi-asserted-by":"crossref","unstructured":"Wu Y, Zhang H, Weng X, Wang H, Zhou Q, Wu Y, et al. Profiling of the germline mutation BRCA1: p.Ile1845fs in a large cohort of Han Chinese breast cancer. Hereditas [Internet]. 2020 Dec [cited 17 Jul 2025];157(1). Available from: https:\/\/hereditasjournal.biomedcentral.com\/articles\/10.1186\/s41065-019-0115-7","DOI":"10.1186\/s41065-019-0115-7"},{"key":"7997_CR40","doi-asserted-by":"crossref","unstructured":"Mahfoudh W, Bettaieb I, Ghedira R, Snoussi K, Bouzid N, Klayech Z, et al. Contribution of BRCA1 5382insC mutation in triple negative breast cancer in Tunisia. J Transl Med [Internet]. 2019 Dec [cited 17 Jul 2025];17(1). Available from: https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-019-1873-8","DOI":"10.1186\/s12967-019-1873-8"},{"issue":"9","key":"7997_CR41","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.3390\/cancers11091246","volume":"11","author":"O Millan Catalan","year":"2019","unstructured":"Millan Catalan O, Campos-Parra AD, V\u00e1zquez-Romo R, De Cant\u00fa D, Jacobo-Herrera N, Morales-Gonz\u00e1lez F, et al. A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population. Cancers. 2019;11(9):1246.","journal-title":"Cancers"},{"issue":"11","key":"7997_CR42","doi-asserted-by":"publisher","first-page":"3515","DOI":"10.31557\/APJCP.2019.20.11.3515","volume":"20","author":"L Nishat","year":"2019","unstructured":"Nishat L, Yesmin ZA, Arjuman F, Rahman SHZ, Banu LA. Identification of Mutation in Exon11 of BRCA1 Gene in Bangladeshi Patients with Breast Cancer. Asian Pac J Cancer Prev. 2019;20(11):3515\u20139.","journal-title":"Asian Pac J Cancer Prev"},{"key":"7997_CR43","doi-asserted-by":"crossref","unstructured":"Behl S, Hamel N, De Ladurantaye M, Lepage S, Lapointe R, Mes-Masson AM, et al. Founder BRCA1\/BRCA2\/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls. Sci Rep [Internet]. 2020 Apr 16 [cited 17 Jul 2025];10(1). Available from: https:\/\/www.nature.com\/articles\/s41598-020-63100-w.","DOI":"10.1038\/s41598-020-63100-w"},{"issue":"5","key":"7997_CR44","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/cancers12051306","volume":"12","author":"JY Hur","year":"2020","unstructured":"Hur JY, Kim JY, Ahn JS, Im YH, Lee J, Kwon M, et al. Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience. Cancers. 2020;12(5):1306.","journal-title":"Cancers"},{"key":"7997_CR45","doi-asserted-by":"crossref","unstructured":"Bakkach J, Mansouri M, Derkaoui T, Loudiyi A, El Fahime E, Barakat A, et al. Contribution of BRCA1 and BRCA2 germline mutations to early onset breast cancer: a series from north of Morocco. BMC Cancer [Internet]. 2020 Dec [cited 17 Jul 2025];20(1). Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07352-9","DOI":"10.1186\/s12885-020-07352-9"},{"key":"7997_CR46","doi-asserted-by":"crossref","unstructured":"Abu-Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, et al. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan. Sci Rep [Internet]. 2020 Oct 16 [cited 17 Jul 2025];10(1). Available from: https:\/\/www.nature.com\/articles\/s41598-020-74250-2.","DOI":"10.1038\/s41598-020-74250-2"},{"issue":"11","key":"7997_CR47","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/cancers13112711","volume":"13","author":"AR Solano","year":"2021","unstructured":"Solano AR, Mele PG, Jalil FS, Liria NC, Podesta EJ, Guti\u00e9rrez LG. Study of the Genetic Variants in BRCA1\/2 and Non-BRCA Genes in a Population-Based Cohort of 2155 Breast\/Ovary Cancer Patients, Including 443 Triple-Negative Breast Cancer Patients, in Argentina. Cancers. 2021;13(11):2711.","journal-title":"Cancers"},{"issue":"4","key":"7997_CR48","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3390\/genes12040519","volume":"12","author":"E Szczerba","year":"2021","unstructured":"Szczerba E, Kami\u0144ska K, Mierzwa T, Misiek M, Kowalewski J, Lewandowska MA. BRCA1\/2 Mutation Detection in the Tumor Tissue from Selected Polish Patients with Breast Cancer Using Next Generation Sequencing. Genes. 2021;12(4):519.","journal-title":"Genes"},{"issue":"3","key":"7997_CR49","doi-asserted-by":"publisher","first-page":"827","DOI":"10.4143\/crt.2021.791","volume":"54","author":"YJ Bang","year":"2022","unstructured":"Bang YJ, Kwon WK, Nam SJ, Kim SW, Chae BJ, Lee SK, et al. Clinicopathological Characterization of Double Heterozygosity for BRCA1 and BRCA2 Variants in Korean Breast Cancer Patients. Cancer Res Treat. 2022;54(3):827\u201333.","journal-title":"Cancer Res Treat"},{"key":"7997_CR50","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/CMAR.S348529","volume":"14","author":"S Stella","year":"2022","unstructured":"Stella S, Vitale SR, Martorana F, Massimino M, Pavone G, Lanzafame K, et al. Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily. Cancer Manag Res. 2022;14:1341\u201352.","journal-title":"Cancer Manag Res"},{"key":"7997_CR51","doi-asserted-by":"crossref","unstructured":"Brahim SM, Zein EE, Bonnet C, Hamed CT, Salame M, Zein MV, et al. Screening of BRCA1\/2 variants in Mauritanian breast cancer patients. BMC Cancer [Internet]. 2022 Dec [cited 17 Jul 2025];22(1). Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09903-8","DOI":"10.1186\/s12885-022-09903-8"},{"issue":"3","key":"7997_CR52","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1002\/cam4.5091","volume":"12","author":"LP Rweyemamu","year":"2023","unstructured":"Rweyemamu LP, G\u00fclta\u015flar BK, Akan G, Dharsee N, Namkinga LA, Lyantagaye SL, et al. Breast cancer in East Africa: Prevalence and spectrum of germline SNV\/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania. Cancer Med. 2023;12(3):3395\u2013409.","journal-title":"Cancer Med"},{"key":"7997_CR53","doi-asserted-by":"crossref","unstructured":"Melki R, Melloul M, Aissaoui S, El Harroudi T, Boukhatem N. Increased prevalence of the founder BRCA1 c.5309G\u2009>\u2009T and recurrent BRCA2 c.1310_1313delAAGA mutations in breast cancer families from Northerstern region of Morocco: evidence of geographical specificity and high relevance for genetic counseling. BMC Cancer [Internet]. 2023 Apr 13 [cited 17 Jul 2025];23(1). Available from: https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-10822-5","DOI":"10.1186\/s12885-023-10822-5"},{"key":"7997_CR54","doi-asserted-by":"crossref","unstructured":"Rioki JN, Muchiri L, Mweu M, Nyagol J, Songok E, Mwangi J et al. BRCA1 and BRCA2 mutations and their clinical relevance in selected women diagnosed with triple-negative breast cancer in Kenya: a descriptive cross-sectional study. Pan Afr Med J [Internet]. 2023 [cited 17 Jul 2025];45. Available from: https:\/\/www.panafrican-med-journal.com\/content\/article\/45\/102\/full","DOI":"10.11604\/pamj.2023.45.102.36431"},{"key":"7997_CR55","doi-asserted-by":"crossref","unstructured":"Zhang Y, Wu H, Gan C, Rao H, Wang Q, Guo X. BRCA1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients. BMC Med Genomics [Internet]. 2024 Jan 2 [cited 17 Jul 2025];17(1). Available from: https:\/\/bmcmedgenomics","DOI":"10.1186\/s12920-023-01772-9"},{"issue":"2","key":"7997_CR56","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cpt.2024.04.002","volume":"3","author":"S Yu","year":"2025","unstructured":"Yu S, Qiu X, Wang Z, Xiao J, Ji H, Shan H, et al. Breast cancer risk associated with BRCA1 and BRCA2 pathogenic variants in the Eastern Chinese population. Cancer Pathog Ther. 2025;3(2):147\u201353.","journal-title":"Cancer Pathog Ther"},{"key":"7997_CR57","doi-asserted-by":"crossref","unstructured":"Hassan AN, Mustafa MS. Breast Cancer High-Penetrance Genes BRCA1 and BRCA2 mutations using next-generation sequencing among Iraqi Kurdish women. Cureus [Internet]. 2024 Jun 11 [cited 17 Jul 2025]; Available from: https:\/\/www.cureus.com\/articles\/260332-breast-cancer-high-penetrance-genes-brca1-and-brca2-mutations-using-next-generation-sequencing-among-iraqi-kurdish-women.","DOI":"10.7759\/cureus.62160"},{"issue":"12","key":"7997_CR58","doi-asserted-by":"publisher","first-page":"e1714","DOI":"10.1093\/oncolo\/oyae214","volume":"29","author":"WS Al Amri","year":"2024","unstructured":"Al Amri WS, Al Amri AH, Al Abri A, Hughes TA, Al Lawati F. BRCA1\/2 mutations and outcomes among Middle Eastern patients with early-onset breast cancer in Oman. Oncologist. 2024;29(12):e1714\u201322.","journal-title":"Oncologist"},{"key":"7997_CR59","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez Rojas LX, Mart\u00ednez LD, Olave Rodr\u00edguez JA, Murillo Rusynke SE, P\u00e9rez Castellano PA, Bola\u00f1os Beltr\u00e1n DA, et al. Germinal mutations among patients with breast cancer in Colombia: is BRCA3 coming? ecancermedicalscience [Internet]. 2025 Feb 27 [cited 17 Jul 2025];19. Available from: https:\/\/ecancer.org\/en\/journal\/article\/1859-germinal-mutations-among-patients-with-breast-cancer-in-colombia-is-brca3-coming.","DOI":"10.3332\/ecancer.2025.1859"},{"key":"7997_CR60","unstructured":"NM_007294.3(BRCA. 1):c.3113A > G (p.Glu1038Gly) AND breast-ovarian cancer, familial 1 - ClinVar - NCBI. Ovarian Cancer."},{"key":"7997_CR61","unstructured":"NM_000059.4(BRCA. 2):c.865A > C (p.Asn289His) AND Breast-ovarian cancer, familial, susceptibility to, 2 - ClinVar - NCBI. Ovarian Cancer."},{"issue":"2","key":"7997_CR62","doi-asserted-by":"publisher","first-page":"483","DOI":"10.21037\/tcr.2019.03.02","volume":"8","author":"M Shen","year":"2019","unstructured":"Shen M, Yang L, Lei T, Xiao L, Li L, Zhang P, et al. BRCA1\/2 mutation spectrum in Chinese early-onset breast cancer. Transl Cancer Res. 2019;8(2):483\u201390.","journal-title":"Transl Cancer Res"},{"issue":"5","key":"7997_CR63","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.3390\/cancers16051072","volume":"16","author":"M Gonzalez-C\u00e1rdenas","year":"2024","unstructured":"Gonzalez-C\u00e1rdenas M, Trevi\u00f1o V. The Impact of Mutational Hotspots on Cancer Survival. Cancers. 2024;16(5):1072.","journal-title":"Cancers"},{"key":"7997_CR64","unstructured":"NM_007294.4(BRCA. 1):c.2635G > T (p.Glu879Ter) AND Breast-ovarian cancer, familial, susceptibility to, 1 - ClinVar - NCBI. Ovarian Cancer."},{"key":"7997_CR65","unstructured":"rs80357251 RefSNP. Report - dbSNP - NCBI."},{"issue":"55","key":"7997_CR66","doi-asserted-by":"publisher","first-page":"30649","DOI":"10.18632\/oncotarget.25769","volume":"9","author":"GHJ Chan","year":"2018","unstructured":"Chan GHJ, Ong PY, Low JJH, Kong HL, Ow SGW, Tan DSP, et al. Clinical genetic testing outcome with multi-gene panel in Asian patients with multiple primary cancers. Oncotarget. 2018;9(55):30649\u201360.","journal-title":"Oncotarget"},{"key":"7997_CR67","doi-asserted-by":"crossref","unstructured":"Kwong A, Ng EKO, Wong CLP, Law FBF, Au T, Wong HN, et al. Identification of BRCA1\/2 Founder mutations in southern chinese breast cancer patients using gene sequencing and high resolution DNA Melting analysis. Toland AE, editor. PLoS ONE. 2012;7(9):e43994.","DOI":"10.1371\/journal.pone.0043994"},{"issue":"2","key":"7997_CR68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1136\/jmedgenet-2017-104947","volume":"55","author":"WX Wen","year":"2018","unstructured":"Wen WX, Allen J, Lai KN, Mariapun S, Hasan SN, Ng PS, et al. Inherited mutations in BRCA1 and BRCA2 in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. J Med Genet. 2018;55(2):97\u2013103.","journal-title":"J Med Genet"},{"key":"7997_CR69","doi-asserted-by":"crossref","unstructured":"Wong ESY, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, et al. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. Npj Genomic Med [Internet]. 2016 Jan 13 [cited 22 Jul 2025];1(1). Available from: https:\/\/www.nature.com\/articles\/npjgenmed20153.","DOI":"10.1038\/npjgenmed.2015.3"},{"issue":"3","key":"7997_CR70","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s10549-009-0385-2","volume":"117","author":"A Kwong","year":"2009","unstructured":"Kwong A, Wong LP, Wong HN, Law FBF, Ng EKO, Tang YH, et al. A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat. 2009;117(3):683\u20136.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"7997_CR71","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.18632\/oncotarget.6834","volume":"7","author":"A Mafficini","year":"2016","unstructured":"Mafficini A, Simbolo M, Parisi A, Rusev B, Luchini C, Cataldo I, et al. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing. Oncotarget. 2016;7(2):1076\u201383.","journal-title":"Oncotarget"},{"issue":"5","key":"7997_CR72","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/ijc.27326","volume":"131","author":"JD Fackenthal","year":"2012","unstructured":"Fackenthal JD, Zhang J, Zhang B, Zheng Y, Hagos F, Burrill DR, et al. High prevalence of BRCA1 and BRCA2 mutations in unselected Nigerian breast cancer patients. Int J Cancer. 2012;131(5):1114\u201323.","journal-title":"Int J Cancer"},{"key":"7997_CR73","doi-asserted-by":"crossref","unstructured":"Oluwagbemiga LA, Oluwole A, Kayode AA. Seventeen years after BRCA1: what is the BRCA mutation status of the breast cancer patients in Africa? \u2013 a systematic review. SpringerPlus [Internet]. 2012 Dec [cited 22 Jul 2025];1(1). Available from: https:\/\/springerplus.springeropen.com\/articles\/10.1186\/2193-1801-1-83","DOI":"10.1186\/2193-1801-1-83"},{"issue":"2","key":"7997_CR74","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/s12687-013-0166-9","volume":"5","author":"T Pal","year":"2014","unstructured":"Pal T, Bonner D, Cragun D, Johnson S, Akbari M, Servais L, et al. BRCA sequencing and large rearrangement testing in young Black women with breast cancer. J Community Genet. 2014;5(2):157\u201365.","journal-title":"J Community Genet"},{"issue":"7","key":"7997_CR75","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-05-0072","volume":"14","author":"JN Weitzel","year":"2005","unstructured":"Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1666\u201371.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"7","key":"7997_CR76","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1158\/1055-9965.EPI-05-0072","volume":"14","author":"JN Weitzel","year":"2005","unstructured":"Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, Herzog J, et al. Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1666\u201371.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"10","key":"7997_CR77","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/gim.2017.14","volume":"19","author":"SM Harrison","year":"2017","unstructured":"Harrison SM, Dolinsky JS, Knight Johnson AE, Pesaran T, Azzariti DR, Bale S, et al. Clinical laboratories collaborate to resolve differences in variant interpretations submitted to ClinVar. Genet Med. 2017;19(10):1096\u2013104.","journal-title":"Genet Med"},{"issue":"5","key":"7997_CR78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324.","journal-title":"Genet Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07997-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07997-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T19:47:44Z","timestamp":1781639264000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07997-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7997"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07997-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"555"}}